Two-year open-label extension data presented at EADV Congress 2026 showed sustained efficacy and a safety profile consistent with prior experience through up to two years of treatment at the approved 8 mg twice-daily dose; no deaths, thrombosis, or major adverse cardiovascular events reported in that cohort. UK (MHRA) approval for severe AA followed in March 2026.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Approved (some countries)
How it works
Oral selective JAK1/JAK2 inhibitor that dampens the autoimmune attack on hair follicles underlying alopecia areata.
Results so far
Durable scalp hair regrowth maintained through Week 108 in the European open-label extension; most treatment-emergent adverse events mild/moderate, discontinuations for AEs uncommon.
What's next
Already approved and commercially launched in the US (July 2025 launch) and newly approved in the UK (March 2026); no additional approvals announced elsewhere.
In India
Owned globally by Sun Pharma (an Indian company) but as of this research pass, Leqselvi has not been launched or approved in India — searches found no CDSCO filing or Indian launch announcement.
Sources
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- Regulator ↗ (accessed 2026-10-17)
- Company announcement ↗ (accessed 2026-10-17)
- Company announcement ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil, or see alopecia areata treatments.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.